HOME >> MEDICINE >> NEWS
New engineering center to transform sensor technology

re creating will be portable and easy to use," said Claire Gmachl, associate professor of electrical engineering at Princeton and the center's director. "Today's state-of-the-art sensors are very sensitive, but require an expert to operate and are bulky and expensive. MIRTHE's vision is to make sensors with the same or better level of sensitivity at a fraction of the size and cost."

The center's deputy directors are Anthony Johnson, professor of physics and professor of computer science and electrical engineering and director of the Center for Advanced Studies in Photonics Research at University of Maryland, Baltimore County, and Matthew Fraser, associate professor of civil and environmental engineering at Rice University.

A key technology enabling the center's work is the quantum cascade laser, which is named for the way the electrons "cascade" through thin layers of material stacked within the device. Gmachl, a member of the Princeton Institute for the Science and Technology of Materials (PRISM), is a pioneer in creating quantum cascade lasers and is a recipient of a 2005 MacArthur "genius grant" in recognition of that work.

The major advantage of quantum cascade lasers is that they emit light in regions of the spectrum known as the mid-infrared. The ability to produce and detect these wavelengths allows scientists to "see" certain chemicals in the same way that sunlight and the human eye reveal everyday objects. "When viewed in the mid-infrared, the world is alive with chemicals like ammonia, carbon, methane, carbon dioxide, carbon monoxide and benzene," said Fraser. "The ability to detect or monitor these gases with a high degree of sensitivity provides important information about the processes that produced them."

"If you look in your house, probably the only laser you'll find is in your CD player, just as 30 years ago you would have found very few transistors in the average home," said Tim Day, chief executive officer of Dayl
'"/>

Contact: Teresa Riordan
triordan@princeton.edu
609-258-9754
Princeton University
2-May-2006


Page: 1 2 3 4 5

Related medicine news :

1. Bioengineering to prevent iron deficiency?
2. Developments in tissue engineering offer new sources for stem cell treatments
3. Scientists progress in successful tissue engineering
4. Tissue engineering for craniofacial reconstruction
5. Medical, IT, engineering experts form advisory panel for electronic health record safety
6. Dental stem cells have been characterized for tooth tissue engineering
7. Tissue engineering experts discuss orthopaedics applications
8. Patient-centered approach can backfire
9. 1 of 2 pediatric kidney disease research centers in world established
10. Test project of patient-centered medical home model endorsed by American College of Physicians
11. Nottingham center to help UK to meet its carbon targets

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New engineering center transform sensor technology

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... long been known for their health benefits, and ... like anti-cancer drugs are delivered to specific tumor ... how to create nanoparticles using natural lipids derived ... them as drug delivery vehicles. UofL scientists Huang-Ge ... team today (May 21, 2013), published their findings ...
(Date:5/21/2013)... Schaumburg, IL (PRWEB) May 21, 2013 ... administration for large, medium, and small organizations, will be ... featuring an experts team from Findley Davies. The presentation ... is up-to-date and in compliance with new Health Care ... ideas to engage employees. , “Benefit Express regularly ...
(Date:5/21/2013)... May 21, 2013 Dr. Francine Kaufman , ... she used with her patients in the 1980s: It weighed several ... For the most part, it could only be used in the ... years since then, and the advantages are greater as well. The ... outside of the body, often on a belt or a pocket. ...
(Date:5/21/2013)... 21, 2013 A plastic surgery ... for plastic surgery SEO services following an Internet ... to name the “Best Plastic Surgery SEO Services”. ... outcome was predictable. Well-known in the plastic surgery ... patients than any other selection based on superior ...
Breaking Medicine News(10 mins):Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2
(Date:5/21/2013)... WESTBURY, N.Y. , May 21, 2013  Vasomedical, Inc. ... specializing in the design, manufacture and sale of medical devices ... today that Dr. Jun Ma , President ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... study is to offer synopsis of the ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: